In metastatic colorectal cancer (mCRC), KRAS and BRAF mutations are well-known markers of resistance and poor prognosis in patients receiving anti-epidermal growth factor receptor (EGFR) monoclonal antibodies [13–16]. This evidence concerns the gene EGFR and metastatic colorectal cancer.